Abstract
To the Editor: We read with great interest the article by Ezekowitz et al on outpatient presentation and management in the setting of atrial fibrillation.1 Management of atrial fibrillation on an outpatient basis should be encouraged. In the case of persistent AF presented by the authors, dronedarone was the antiarhythmic drug choosen for rhythm control, and started before cardioversion. Dronedarone is a new agent in the pharmacological arsenal for maintaining sinus …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
